Do analysts rate JAGX or AMPE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jaguar Animal Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is JAGX or AMPE more profitable?

Ampio Pharmaceuticals has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -169.04%. Company Net Margins Return on Equity Return on Assets Jaguar Animal Health -169.04% N/A -115.55% Ampio Pharmaceuticals N/A N/A N/A

Which has preferable earnings and valuation, WINT or AMPE?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Windtree Therapeutics N/A N/A -$1.79M -$8.77 N/A Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A

Is WINT or AMPE more profitable?

Ampio Pharmaceuticals' return on equity of 0.00% beat Windtree Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Windtree Therapeutics N/A -207.34% -50.19% Ampio Pharmaceuticals N/A N/A N/A

Which has better valuation and earnings, AMPE or HEPA?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A

Is AMPE or HEPA more profitable?

Ampio Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A Hepion Pharmaceuticals N/A -812.56% -207.31%

Which has preferable valuation & earnings, AMPE or BPTSY?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is AMPE or BPTSY more profitable?

Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A Biophytis N/A N/A N/A

Is AMPE or SRNE more profitable?

Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A Sorrento Therapeutics N/A N/A N/A

Ampio Pharmaceuticals (AMPE) Competitors

$0.18 0.00 (0.00%)

As of 07/30/2026

Compare

AMPE vs. JAGX, WINT, HEPA, BPTSY, and SRNE

Should you buy Ampio Pharmaceuticals stock or one of its competitors? MarketBeat compares Ampio Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ampio Pharmaceuticals include Jaguar Animal Health (JAGX), Windtree Therapeutics (WINT), Hepion Pharmaceuticals (HEPA), Biophytis (BPTSY), and Sorrento Therapeutics (SRNE).

How does Ampio Pharmaceuticals compare to Jaguar Animal Health?

Jaguar Animal Health (NASDAQ:JAGX) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Ampio Pharmaceuticals has lower revenue, but higher earnings than Jaguar Animal Health. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jaguar Animal Health	$11.51M	0.05	-$53.43M	-$591.92	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

In the previous week, Jaguar Animal Health's average media sentiment score of 0.94 beat Ampio Pharmaceuticals' score of 0.00 indicating that Jaguar Animal Health is being referred to more favorably in the media.

Company	Overall Sentiment
Jaguar Animal Health	Positive
Ampio Pharmaceuticals	Neutral

Jaguar Animal Health has a beta of -0.11, meaning that its stock price is 111% less volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, meaning that its stock price is 496% more volatile than the broader market.

Ampio Pharmaceuticals has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -169.04%.

Company	Net Margins	Return on Equity	Return on Assets
Jaguar Animal Health	-169.04%	N/A	-115.55%
Ampio Pharmaceuticals	N/A	N/A	N/A

12.0% of Jaguar Animal Health shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 2.0% of Jaguar Animal Health shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jaguar Animal Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Ampio Pharmaceuticals beats Jaguar Animal Health on 6 of the 11 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Windtree Therapeutics?

Windtree Therapeutics (NASDAQ:WINT) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Ampio Pharmaceuticals' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Windtree Therapeutics	N/A	-207.34%	-50.19%
Ampio Pharmaceuticals	N/A	N/A	N/A

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Windtree Therapeutics	N/A	N/A	-$1.79M	-$8.77	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

Windtree Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market.

29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Windtree Therapeutics' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Windtree Therapeutics	Neutral
Ampio Pharmaceuticals	Neutral

Summary

Windtree Therapeutics and Ampio Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Hepion Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
Hepion Pharmaceuticals	Neutral

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ampio Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Ampio Pharmaceuticals has a beta of 5.96, meaning that its stock price is 496% more volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

Summary

Ampio Pharmaceuticals beats Hepion Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Biophytis?

Ampio Pharmaceuticals (NYSE:AMPE) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Biophytis	N/A	N/A	N/A

Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
Biophytis	Neutral

Summary

Ampio Pharmaceuticals beats Biophytis on 3 of the 4 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Sorrento Therapeutics?

Ampio Pharmaceuticals (NYSE:AMPE) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Ampio Pharmaceuticals has higher earnings, but lower revenue than Sorrento Therapeutics. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
Sorrento Therapeutics	$60.32M	0.00	-$572.84M	-$0.17	N/A

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
Sorrento Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Sorrento Therapeutics	N/A	N/A	N/A

Ampio Pharmaceuticals has a beta of 5.96, meaning that its stock price is 496% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market.

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Ampio Pharmaceuticals beats Sorrento Therapeutics on 4 of the 7 factors compared between the two stocks.

Get Ampio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMPE vs. The Competition

Export

Metric	Ampio Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$208K	$12.83B	$7.22B	$23.72B
Dividend Yield	N/A	2.72%	2.59%	4.20%
P/E Ratio	-0.02	793.97	280.89	30.99
Price / Sales	N/A	935.37	639.94	13.91
Price / Cash	N/A	76.57	71.02	31.71
Price / Book	0.05	10.88	11.07	4.62
Net Income	-$8.63M	$2.82B	$3.49B	$1.07B
7 Day Performance	N/A	-0.19%	-0.24%	0.36%
1 Month Performance	N/A	-3.32%	-2.98%	-0.19%
1 Year Performance	N/A	155.35%	61.99%	19.11%

Ampio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	20
JAGX Jaguar Animal Health	0.5807 of 5 stars	$1.33 +5.6%	N/A	-98.6%	$760K	$11.51M	N/A	50	Gap Up
WINT Windtree Therapeutics	N/A	$0.01 flat	N/A	-99.9%	$625K	N/A	N/A	30	Gap Up
HEPA Hepion Pharmaceuticals	N/A	$0.05 flat	N/A	+9.3%	$612K	N/A	N/A	20	Gap Down
BPTSY Biophytis	N/A	$0.25 flat	N/A	N/A	$586K	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AMPE) was last updated on 8/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ampio Pharmaceuticals (AMPE) Competitors

AMPE vs. JAGX, WINT, HEPA, BPTSY, and SRNE

How does Ampio Pharmaceuticals compare to Jaguar Animal Health?

Summary

How does Ampio Pharmaceuticals compare to Windtree Therapeutics?

Summary

How does Ampio Pharmaceuticals compare to Hepion Pharmaceuticals?

Summary

How does Ampio Pharmaceuticals compare to Biophytis?

Summary

How does Ampio Pharmaceuticals compare to Sorrento Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPE vs. The Competition

Ampio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ampio Pharmaceuticals (AMPE) Competitors

AMPE vs. JAGX, WINT, HEPA, BPTSY, and SRNE

How does Ampio Pharmaceuticals compare to Jaguar Animal Health?

Which has preferable valuation & earnings, JAGX or AMPE?

Does the media favor JAGX or AMPE?

Which has more risk and volatility, JAGX or AMPE?

Is JAGX or AMPE more profitable?

Do insiders and institutionals believe in JAGX or AMPE?

Do analysts rate JAGX or AMPE?

Summary

How does Ampio Pharmaceuticals compare to Windtree Therapeutics?

Is WINT or AMPE more profitable?

Which has preferable earnings and valuation, WINT or AMPE?

Which has more volatility and risk, WINT or AMPE?

Do institutionals and insiders believe in WINT or AMPE?

Does the media favor WINT or AMPE?

Summary

How does Ampio Pharmaceuticals compare to Hepion Pharmaceuticals?

Which has better valuation and earnings, AMPE or HEPA?

Does the media prefer AMPE or HEPA?

Do institutionals and insiders believe in AMPE or HEPA?

Is AMPE or HEPA more profitable?

Which has more risk & volatility, AMPE or HEPA?

Summary

How does Ampio Pharmaceuticals compare to Biophytis?

Is AMPE or BPTSY more profitable?

Which has more volatility & risk, AMPE or BPTSY?

Which has preferable valuation & earnings, AMPE or BPTSY?

Do insiders and institutionals hold more shares of AMPE or BPTSY?

Does the media refer more to AMPE or BPTSY?

Summary

How does Ampio Pharmaceuticals compare to Sorrento Therapeutics?

Which has stronger earnings and valuation, AMPE or SRNE?

Does the media favor AMPE or SRNE?

Is AMPE or SRNE more profitable?

Which has more volatility & risk, AMPE or SRNE?

Do institutionals & insiders have more ownership in AMPE or SRNE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPE vs. The Competition

Ampio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools